Therapy
Ocrelizumab
Humanised IgG1 anti-CD20 mAb: lower immunogenicity than rituximab (human Fc+variable), similar ADCC mechanism.
Also called: Ocrevus, OCR, anti-CD20 MS
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 4 and is affected by 1 concepts — mostly 1 cell, 1 receptor, 1 disease.
- 3Where it sits: therapy, trial on the 15-step immune chain.
What it does
ORATORIO trial (PPMS): first ever positive Phase 3 trial in PPMS history (CDP slowed 24%, HR 0.76, p=0.003), supported a B-cell contribution to progressive MS.
Its connections at a glance
Each dot is a concept directly linked to Ocrelizumab. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I012 · concept status: established. Select any connection above to inspect evidence for that specific link.